BMRN

BioMarin Pharmaceutical Inc.

84.10 USD
+0.01 (+0.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioMarin Pharmaceutical Inc. stock is down -0.72% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64% of the previous 25 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
24 Jun 14:44 19 Jul, 2024 80.00 CALL 114 1616
24 Jun 15:01 19 Jul, 2024 80.00 CALL 50 1616
05 Jul 13:39 18 Oct, 2024 75.00 CALL 60 244
05 Jul 13:42 18 Oct, 2024 75.00 CALL 40 244
05 Jul 16:49 20 Sep, 2024 90.00 CALL 130 3049
08 Jul 18:40 20 Sep, 2024 87.50 CALL 250 127
16 Jul 14:25 16 Aug, 2024 90.00 CALL 1500 219
18 Jul 15:55 16 Aug, 2024 87.50 CALL 229 463
19 Jul 14:36 20 Sep, 2024 85.00 CALL 58 1745
19 Jul 14:40 20 Sep, 2024 85.00 CALL 500 1745

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.